Inhibition of glycogen synthase kinase-3β downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A

Brain Research

Volumn 1252, Issue , 2009, Pages 66-75

  Martin, Ludovic ^a   Magnaudeix, Amandine ^a   Esclaire, Françoise ^a,b   Yardin, Catherine ^a,b   Terro, Faraj ^a,b  

^a UNIVERSITÉ DE LIMOGES   (France)

^b Hopital de la Mere et de l'Enfant   (France)

Author keywords

Alzheimer's disease; Glycogen synthase kinase 3 ; Lithium; Protein phosphatase 2A; Protein phosphatase 2B; Tau

Indexed keywords

CALCINEURIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; ROSCOVITINE; TACROLIMUS; TAU PROTEIN;

ARTICLE; DOSE RESPONSE; DOWN REGULATION; ENZYME INHIBITION; NERVE CELL CULTURE; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CALCINEURIN; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 5; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; INDOLES; LITHIUM CHLORIDE; NEURONS; OKADAIC ACID; OXIMES; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PURINES; RATS; RATS, WISTAR; TACROLIMUS; TAU PROTEINS;

EID: 58349114277     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.11.057     Document Type: Article

References (51)

1. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., and Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 453 (1999) 260-264
2. Amadoro G., Ciotti M.T., Costanzi M., Cestari V., Calissano P., and Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2892-2897
3. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., and Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336 (1993) 417-424
4. Beaulieu J.M., Gainetdinov R.R., and Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 28 (2007) 166-172
5. Chen S., Li B., Grundke-Iqbal I., and Iqbal K. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J. Biol. Chem. 283 (2008) 10513-10521
6. Dickey C.A., Ash P., Klosak N., Lee W.C., Petrucelli L., Hutton M., and Eckman C.B. Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol. Neurodegener. 1 (2006) 6
7. Embi N., Rylatt D.B., and Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107 (1980) 519-527
8. Flaherty D.B., Soria J.P., Tomasiewicz H.G., and Wood J.G. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res. 62 (2000) 463-472
9. Goedert M., Spillantini M.G., Jakes R., Rutherford D., and Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3 (1989) 519-526
10. Gong C.X., Singh T.J., Grundke-Iqbal I., and Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem. 61 (1993) 921-927
11. Grimes C.A., and Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65 (2001) 391-426
12. Hooper C., Killick R., and Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104 (2008) 1433-1439
13. Ikegami S., Harada A., and Hirokawa N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci. Lett. 279 (2000) 129-132
14. Ivaska J., Nissinen L., Immonen N., Eriksson J.E., Kahari V.M., and Heino J. Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol. Cell. Biol. 22 (2002) 1352-1359
15. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry 4 (1999) 117-128
16. Kins S., Crameri A., Evans D.R., Hemmings B.A., Nitsch R.M., and Gotz J. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem. 276 (2001) 38193-38200
17. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8455-8459
18. Li X., Bijur G.N., and Jope R.S. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4 (2002) 137-144
19. Liang Z., Liu F., Iqbal K., Grundke-Iqbal I., Wegiel J., and Gong C.X. decrease of protein phosphatase 2a and its association with accumulation and hyperphosphorylation of tau in down syndrome. J. Alzheimer's Dis. 13 (2008) 295-302
20. Lin C.F., Chen C.L., Chiang C.W., Jan M.S., Huang W.C., and Lin Y.S. GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J. Cell. Sci. 120 (2007) 2935-2943
21. Liu F., Grundke-Iqbal I., Iqbal K., and Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22 (2005) 1942-1950
22. Liu G.P., Zhang Y., Yao X.Q., Zhang C.E., Fang J., Wang Q., and Wang J.Z. Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms. Neurobiol. Aging 29 9 (2007) 1348-1358
23. Liu R., Pei J.J., Wang X.C., Zhou X.W., Tian Q., Winblad B., and Wang J.Z. Acute anoxia induces tau dephosphorylation in rat brain slices and its possible underlying mechanisms. J. Neurochem. 94 (2005) 1225-1234
24. Liu R., Zhou X.W., Tanila H., Bjorkdahl C., Wang J.Z., Guan Z.Z., Cao Y., Gustafsson J.A., Winblad B., and Pei J.J. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J. Cell. Mol. Med. 12 (2008) 241-257
25. Lochhead P.A., Kinstrie R., Sibbet G., Rawjee T., Morrice N., and Cleghon V. A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol. Cell 24 (2006) 627-633
26. Maeda S., Sahara N., Saito Y., Murayama S., Ikai A., and Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci. Res. 54 (2006) 197-201
27. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., and Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243 (1997) 527-536
28. Meijer L., Skaltsounis A.L., Magiatis P., Polychronopoulos P., Knockaert M., Leost M., Ryan X.P., Vonica C.A., Brivanlou A., Dajani R., Crovace C., Tarricone C., Musacchio A., Roe S.M., Pearl L., and Greengard P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 10 (2003) 1255-1266
29. Meske V., Albert F., and Ohm T.G. Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau. J. Biol. Chem. 283 (2008) 100-109
30. Nakashima H., Ishihara T., Suguimoto P., Yokota O., Oshima E., Kugo A., Terada S., Hamamura T., Trojanowski J.Q., Lee V.M., and Kuroda S. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 110 (2005) 547-556
31. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., and Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6990-6995
32. Papkoff J., and Aikawa M. WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells. Biochem. Biophys. Res. Commun. 247 (1998) 851-858
33. Planel E., Yasutake K., Fujita S.C., and Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J. Biol. Chem. 276 (2001) 34298-34306
34. Rametti A., Esclaire F., Yardin C., and Terro F. Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J. Biol. Chem. 279 (2004) 54518-54528
35. Rametti A., Esclaire F., Yardin C., Cogne N., and Terro F. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection. Neurosci. Lett. 434 (2008) 93-98
36. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., and Ferreira A. Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6364-6369
37. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., and Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007) 750-754
38. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., and Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
39. Seeling J.M., Miller J.R., Gil R., Moon R.T., White R., and Virshup D.M. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 283 (1999) 2089-2091
40. Seubert P., Mawal-Dewan M., Barbour R., Jakes R., Goedert M., Johnson G.V., Litersky J.M., Schenk D., Lieberburg I., Trojanowski J.Q., et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J. Biol. Chem. 270 (1995) 18917-18922
41. Stambolic V., and Woodgett J.R. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J. 303 Pt 3 (1994) 701-704
42. Tajes M., Gutierrez-Cuesta J., Folch J., Ferrer I., Caballero B., Smith M.A., Casadesus G., Camins A., and Pallas M. Lithium treatment decreases activities of tau kinases in a murine model of senescence. J. Neuropathol. Exp. Neurol. 67 (2008) 612-623
43. Tanimukai H., Grundke-Iqbal I., and Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am. J. Pathol. 166 (2005) 1761-1771
44. Terwel D., Muyllaert D., Dewachter I., Borghgraef P., Croes S., Devijver H., and Van Leuven F. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 172 (2008) 786-798
45. Tsuji S., Morinobu S., Tanaka K., Kawano K., and Yamawaki S. Lithium, but not valproate, induces the serine/threonine phosphatase activity of protein phosphatase 2A in the rat brain, without affecting its expression. J. Neural Transm. 110 (2003) 413-425
46. Vogelsberg-Ragaglia V., Schuck T., Trojanowski J.Q., and Lee V.M. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp. Neurol. 168 (2001) 402-412
47. Walton J.R. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. J. Inorg. Biochem. 101 (2007) 1275-1284
48. Wang J.Z., Gong C.X., Zaidi T., Grundke-Iqbal I., and Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J. Biol. Chem. 270 (1995) 4854-4860
49. Wang Q.M., Fiol C.J., DePaoli-Roach A.A., and Roach P.J. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J. Biol. Chem. 269 (1994) 14566-14574
50. Yoon S.Y., Choi J.E., Huh J.W., Hwang O., Nam Hong H., and Kim D. Inactivation of GSK-3beta in okadaic acid-induced neurodegeneration: relevance to Alzheimer's disease. NeuroReport 16 (2005) 223-227
51. Zahler S., Tietze S., Totzke F., Kubbutat M., Meijer L., Vollmar A.M., and Apostolakis J. Inverse in silico screening for identification of kinase inhibitor targets. Chem. Biol. 14 (2007) 1207-1214